345 related articles for article (PubMed ID: 29061442)
1. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
Du R; Wang L; Xu H; Wang Z; Zhang T; Wang M; Ning Y; Deng F; Hu Z; Wang H; Li Y
Antiviral Res; 2017 Nov; 147():131-141. PubMed ID: 29061442
[TBL] [Abstract][Full Text] [Related]
2. Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.
Krawczyk A; Krauss J; Eis-Hübinger AM; Däumer MP; Schwarzenbacher R; Dittmer U; Schneweis KE; Jäger D; Roggendorf M; Arndt MA
J Virol; 2011 Feb; 85(4):1793-803. PubMed ID: 21123390
[TBL] [Abstract][Full Text] [Related]
3. Entry inhibition of HSV-1 and -2 protects mice from viral lethal challenge.
Clementi N; Criscuolo E; Cappelletti F; Quaranta P; Pistello M; Diotti RA; Sautto GA; Tarr AW; Mailland F; Concas D; Burioni R; Clementi M; Mancini N
Antiviral Res; 2017 Jul; 143():48-61. PubMed ID: 28396205
[TBL] [Abstract][Full Text] [Related]
4. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization.
Komala Sari T; Gianopulos KA; Nicola AV
J Virol; 2020 Feb; 94(5):. PubMed ID: 31826995
[TBL] [Abstract][Full Text] [Related]
5. Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.
Criscuolo E; Castelli M; Diotti RA; Amato V; Burioni R; Clementi M; Ambrosi A; Mancini N; Clementi N
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867302
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the epitope for a herpes simplex virus glycoprotein B-specific monoclonal antibody with high protective capacity.
Däumer MP; Schneider B; Giesen DM; Aziz S; Kaiser R; Kupfer B; Schneweis KE; Schneider-Mergener J; Reineke U; Matz B; Eis-Hübinger AM
Med Microbiol Immunol; 2011 May; 200(2):85-97. PubMed ID: 20931340
[TBL] [Abstract][Full Text] [Related]
7. Patient-Specific Neutralizing Antibody Responses to Herpes Simplex Virus Are Attributed to Epitopes on gD, gB, or Both and Can Be Type Specific.
Cairns TM; Huang ZY; Gallagher JR; Lin Y; Lou H; Whitbeck JC; Wald A; Cohen GH; Eisenberg RJ
J Virol; 2015 Sep; 89(18):9213-31. PubMed ID: 26109729
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.
Wang K; Tomaras GD; Jegaskanda S; Moody MA; Liao HX; Goodman KN; Berman PW; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Haynes BF; Cohen JI
J Virol; 2017 Oct; 91(19):. PubMed ID: 28701403
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
Hook LM; Cairns TM; Awasthi S; Brooks BD; Ditto NT; Eisenberg RJ; Cohen GH; Friedman HM
PLoS Pathog; 2018 May; 14(5):e1007095. PubMed ID: 29791513
[TBL] [Abstract][Full Text] [Related]
10. A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus.
Ramsey NLM; Visciano M; Hunte R; Loh LN; Burn Aschner C; Jacobs WR; Herold BC
J Virol; 2020 Jun; 94(13):. PubMed ID: 32295919
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to the distinct antigenic sites on glycoproteins C and B and their protective abilities in herpes simplex virus infection.
Bystrická M; Petríková M; Zatovicová M; Soláriková L; Kostolanský F; Mucha V; Russ G
Acta Virol; 1997 Feb; 41(1):5-12. PubMed ID: 9199708
[TBL] [Abstract][Full Text] [Related]
13. Using Antibodies and Mutants To Localize the Presumptive gH/gL Binding Site on Herpes Simplex Virus gD.
Atanasiu D; Saw WT; Lazear E; Whitbeck JC; Cairns TM; Lou H; Eisenberg RJ; Cohen GH
J Virol; 2018 Dec; 92(24):. PubMed ID: 30282715
[TBL] [Abstract][Full Text] [Related]
14. The gH-gL complex of herpes simplex virus (HSV) stimulates neutralizing antibody and protects mice against HSV type 1 challenge.
Peng T; Ponce-de-Leon M; Jiang H; Dubin G; Lubinski JM; Eisenberg RJ; Cohen GH
J Virol; 1998 Jan; 72(1):65-72. PubMed ID: 9420201
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the antibody neutralization of herpes simplex virus.
Lee CC; Lin LL; Chan WE; Ko TP; Lai JS; Wang AH
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):1935-45. PubMed ID: 24100313
[TBL] [Abstract][Full Text] [Related]
16. Development of a highly effective combination monoclonal antibody therapy against Herpes simplex virus.
Seyfizadeh N; Kalbermatter D; Imhof T; Ries M; Müller C; Jenner L; Blumenschein E; Yendrzheyevskiy A; Grün F; Moog K; Eckert D; Engel R; Diebolder P; Chami M; Krauss J; Schaller T; Arndt M
J Biomed Sci; 2024 May; 31(1):56. PubMed ID: 38807208
[TBL] [Abstract][Full Text] [Related]
17. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.
Awasthi S; Belshe RB; Friedman HM
J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496
[TBL] [Abstract][Full Text] [Related]
18. A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D.
Tian R; Ju F; Yu M; Liang Z; Xu Z; Zhao M; Qin Y; Lin Y; Huang X; Chang Y; Li S; Ren W; Lin C; Xia N; Huang C
Antiviral Res; 2022 May; 201():105298. PubMed ID: 35341808
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a type-common human recombinant monoclonal antibody to herpes simplex virus with high therapeutic potential.
De Logu A; Williamson RA; Rozenshteyn R; Ramiro-Ibañez F; Simpson CD; Burton DR; Sanna PP
J Clin Microbiol; 1998 Nov; 36(11):3198-204. PubMed ID: 9774565
[TBL] [Abstract][Full Text] [Related]
20. Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
Wang M; Jiang S; Zhou L; Wang C; Mao R; Ponnusamy M
Arch Virol; 2017 Mar; 162(3):701-711. PubMed ID: 27868164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
